跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2007-004671-19-BE
EUCTR2007-004671-19-BE进行中（未招募）1 期

A Phase 2, Single-Arm Study of Pralatrexate in Patients with Advancedor Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Allos Therapeutics, Inc.0 个研究点目标入组 50 人开始时间: 2008年3月27日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
50
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •1. Histologically confirmed TCC (> 50% TCC in tumor) of the urinary bladder. Fine needle aspirate will not be accepted.
  • •2. Relapsed or progressed after treatment with a platinum- and/or methotrexate-based systemic chemotherapy regimen. No more than 1 prior regimen is permitted in the recurrent/metastatic setting. Patient has had a chemotherapy-free interval of at least 12 months from the last dose of chemotherapy if the most recent prior regimen was in the neoadjuvant or adjuvant setting and has had at least a 6-month chemotherapy-free interval from regimens in the recurrent/metastatic setting. Patient has recovered from the toxic effects of prior therapy. Previous intravesical therapy is allowed. Prior surgical resection is allowed, as long as the patient has recovered from the procedure.
  • •3. Measurable disease, outside a previously irradiated region, per Response Evaluation Criteria in Solid Tumors (RECIST) (see http://www.eortc.be/recist/).
  • •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • •5. = 18 years of age.
  • •6. Adequate hematologic, hepatic, and renal function as defined by: Hgb = 10 g/dL (= 100 g/L); WBC count = 2500 cells/mm3 (= 2.5 x 10^9 cells/L); absolute neutrophil count (ANC)= 1500 cells/mm3 (= 1.5 x 10^9 cells/L); platelet count = 100,000/mm3; calculated CrCl of = 50 mL/min; total bilirubin = 1.5 x upper limit of normal (ULN); and aspartate aminotransferase (AST, serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT, serum glutamic-pyruvic transaminase [SGPT]) = 3 x ULN.
  • •7. The patient has been on a regimen of 1-1.25 mg PO QD of folic acid for at least 7 days prior to enrollment and has received 1 mg IM of vitamin B12 within 10 weeks of enrollment.
  • •8. Women of childbearing potential have a negative serum pregnancy test within 14 days prior to enrollment and must agree to practice a medically acceptable contraceptive regimen from enrollment until at least 30 days after the last administration of pralatrexate. Patients who are postmenopausal for at least 1 year (> 12 months since last menses) or are surgically sterilized do not require this test.
  • •9. Men who are not surgically sterile and whose partner is of childbearing potential must be practicing a medically safe and effective contraceptive regimen from the time of pralatrexate initiation, and agree to continue practicing until at least 90 days after the last administration of pralatrexate.
  • •10. Accessible for repeat dosing and follow-up.
  • •11. Given written informed consent (IC).
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • •1. Active concurrent primary malignancy or prior malignancies occurring within 5 years (except non-melanoma skin cancer, in situ carcinoma of the cervix, or occult, indolent carcinoma of the prostate [undetectable prostate-specific antigen, Gleason score = 7, no seminal vesicle invasion, and no extraprostatic extension]). If there is a history of prior malignancies other than those exceptions listed above, the patient must be disease free for = 5 years. Patients with other prior malignancies less than 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease. In the case of a single extrapelvic metastatic site, irrespective of the patient having a history of previous malignancy, a biopsy proof of the metastatic diseased organ will be necessary.
  • •2. More than 1 previous chemotherapeutic regimen in the recurrent/metastatic setting.
  • •3. Evidence of clinically significant active thirdspace phenomenon; ie, peripheral edema (= +2), active pleural effusions, or ascites.
  • •4. Use of any investigational drugs, biologics, or devices within 28 days prior to study
  • •enrollment.
  • •5. Previous exposure to other antifolates (eg, methotrexate, pemetrexed [Alimta]). Previous methotrexate is allowed, only if it was part of a methotrexate, vinblastine, doxorubicin (Adriamycin), and cisplatin (M-VAC) or methotrexate, cisplatin, and vinblastine (MCV) regimen.
  • •6. Previous exposure to pralatrexate.
  • •7. Women who are pregnant or breastfeeding.
  • •8. Congestive Heart Failure Class III/IV according to New York Heart Association (NYHA) Functional Classification.
  • •9. Uncontrolled hypertension.
  • •10. Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of < 100 mm3 or detectable viral load within the past 3 months, and is receiving combination anti-retroviral therapy.
  • •11. CNS metastatic disease.
  • •12. Major surgery within 2 weeks of study enrollment.
  • •13. Radiation therapy within 4 weeks (within 3 months for RT to the pelvis) prior to study enrollment.
  • •14. Active infection or any serious underlying medical condition, which would impair the ability of the patient to receive protocol treatment.
  • •15. Dementia or significantly altered mental status that would prohibit the understanding and giving of IC or limit study compliance.

研究者

相似试验

进行中（未招募）
不适用
A Phase 2, Single-Arm Study of Pralatrexate in Patients with Advancedor Metastatic Relapsed Transitional Cell Carcinoma of the Urinary BladderAdvanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary BladderMedDRA version: 9.1Level: LLTClassification code 10007294Term: Carcinoma bladder recurrent
EUCTR2007-004671-19-FRAllos Therapeutics, Inc.50
已完成
2 期
Phase II study of pematrexed plus carboplatin in previously untreated non-small cell, non-squamous cell lung cancernresectable non-small cell lung cancer with EGFR mutations (non-squamous histology)
JPRN-UMIN000002846Hokkaido Lung Cancer Study Group40
已完成
不适用
Phase II study of Paclitaxel and Nedaplatin for previously untreated patients with advanced squamous cell lung cancer.Squamous cell lung cancer
JPRN-UMIN000008872Tochigi Cancer Center17
进行中（未招募）
1 期
A Study in Patients with advanced Ovarian CancerPatients with platinum-resistant or platinum-refractory high-gradeserous ovarian, primary peritoneal, or fallopian tube cancer who have failed standard of care treatment.MedDRA version: 20.0Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016182Term: Fallopian tube cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061269Term: Malignant peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-004009-42-ESilly S.A.169
进行中（未招募）
1 期
A Study in Patients with advanced Ovarian CancerPatients with platinum-resistant or platinum-refractory high-gradeserous ovarian, primary peritoneal, or fallopian tube cancer who have failed standard of care treatment.MedDRA version: 21.1Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10016182Term: Fallopian tube cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10061269Term: Malignant peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-004009-42-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER169